Tuesday, 27 April 2021

Orthopedic Trauma Devices Market To Reach Beyond US$ 7.7 Billion By 2025 - Coherent Market Insights

 

The Global Orthopedic Trauma Devices Market, by Fixator Type (Internal Fixator [Screws, Plates, Nails, and Others], External fixator), by Material (Non-absorbable [Titanium, Stainless steel, and Other] and Bio-absorbable), by End User (Hospitals, Orthopedic Clinic, and Ambulatory Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 4,915 million in 2016 and is projected to exhibit a CAGR of 5.3% over the forecast period (2017 – 2025).

The orthopedic trauma devices market is expected to gain significant traction with rising incidence of fractures due to road accidents, falls, and old age. Furthermore, increasing number of people suffering from osteoarthritis is expected to be another factor for growth of the market. For instance, by 2040, the number of adults in the U.S., with doctor-diagnosed arthritis is projected to be 78.4 million, according to International Osteoporosis Foundation statistics, and around 1.6 million hip fractures occur worldwide each year.

This number could reach 4.5 million by 2050. Therefore, there is increasing demand for plates, screws, nails, and other implants such as staples and bridge for treatment of fractures. Emerging economies such as China and India are characterized by high prevalence of falls and road injuries. According to World Health Organization factsheet in 2018, 80% of worldwide fatal falls are reported from low and middle income countries. Asia Pacific region faces one of highest incidence of falls worldwide according to World Health Organization’s 2018 factsheet. This is another factor aiding in growth of the market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/130

New product launches, collaboration, and mergers by key players is expected to drive growth of the orthopedic trauma devices market

Key players are launching new and innovative products in screws, plating systems, and other orthopedic trauma devices, in order to cater to increasing demand by end users, thereby expanding their market share. For instance, in 2017, DePuy Synthes received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VIPER and EXPEDIUM Fenestrated Screw Systems. This system provide stabilization and palliative treatment for patients suffering from spinal cord compression, due to advanced stage tumors.

In 2015, DePuy Synthes launched two new variable angle plating systems featuring its proprietary variable angle locking technology. DePuy Synthes also launched an external circular fixation device named MAXFRAME Multi-Axial Correction System, in 2017, which can be used to correct bone or soft tissue deformities in the arm, leg, foot or ankle. In 2016, Zimmer Biomet received 510(k) clearance from the U.S. Food and Drug Administration for the Unite3D Bridge Fixation System. In 2017, company (Zimmer Biomet) showcased its innovative products in trauma segment such as A.L.P.S. Proximal Humerus Plating System, N-Force Fixation System. In 2015, Smith & Nephew launched its TRIGEN META-TAN (Trochanteric Antegrade Nail) System at the Orthopedic Trauma Association’s (OTA) annual meeting in San Diego, U.S.

Browse 65 Market Data Tables and 40 Figures spread through 180 Pages and in-depth TOC on “Orthopedic Trauma Devices Market- by Fixator Type (Internal Fixator [Screws, Plates, Nails, and Others], External fixator), by Material (Non-absorbable [Titanium, Stainless steel stand, and Other] and Bio-absorbable), by End User (Hospitals, Orthopedic Clinic, and Ambulatory Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2025”

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/orthopedic-trauma-devices-market-130

Companies are focusing on collaborative agreements, in order to expand their presence in emerging markets. For instance, in 2016, Stryker Corporation entered into collaboration with Indo UK Institute of Health's (IUIH) Medicity Program, to serve as a preferred partner in the orthopedic areas of hip, knee, and trauma products and services in India. Smith and Nephew launched Atlas Hip Fracture Nail in emerging markets such as South Africa and India, in 2017, to expand presence in these regions. Companies are also focusing on strategic mergers and acquisitions, in order to expand its footprint in the orthopedic trauma devices market.

For instance, in 2015, Smith & Nephew plc acquired the trauma and orthopedics business of DeOst LLC and DC LLC, which is a manufacturing company in DeOst group from Russia. DeOst distributed Smith & Nephew’s products in Russia. In 2013, Smith & Nephew bought Adler Mediequip Private Limited, which was a mid-tier trauma business in India, and also acquired a direct presence in Turkey through buying assets related to the distribution of its orthopedic reconstruction, trauma, and sports medicine products in Turkey. In March, 2016 Zimmer Biomet entered into an exclusive global distribution agreement with CelgenTek Innovations Corporation, for its N-Force Fixation System and iN3 Cement.

Key Takeaways of the Orthopedic Trauma Devices Market:

The global orthopedic trauma devices market is expected to exhibit a CAGR of 7.3 % over the forecast period, owing to growth in injuries from trauma associated incidences and rising population suffering from bone degenerative diseases.

Among fixator types, internal fixator segment, which includes the screws, nails, plates, and specialized implants is expected to be the dominant in the market, due to increasing demand of these devices in trauma incidence as trauma is often characterized by bone fracture. Among material types, metallic devices segment is expected to account for larger share, due to the easy availability and low cost. However, bio-absorbable is slowly gaining traction in the market. Amongst end users, hospital segment is expected to be the largest segment, in terms of revenue share, to large number of orthopedic trauma patients admitted in hospitals as compared to ambulatory surgical centers and orthopedic clinics. According to study published in journal Injury in 2016 there were 20,659,684 traumatic injury discharges from US hospitals between 2000 and 2011.

North America is expected to be the dominant market for orthopedic trauma devices, due to high incidence of sport related injuries, high probability of fracture in population aged over 50, and rising geriatric population(47.8 million in 2015).

Some of the major players operating in orthopedic trauma devices market are DePuy Synthes (a Johnson & Johnson Company) Stryker Corporation, Zimmer Holding Inc., Smith & Nephew plc, and Biomet, Inc. Other prominent players are Braun Melsungen AG, Arthrax, Inc., Medtronic Inc., Integra LifeSciences Corporation, Orthofix International, NuVasive, and Conmed Corporation

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/130

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Gastroscopy Devices Market Size, Trends, Shares, Insights and Forecast – 2018-2026

 

Gastroscopy Devices Market: Drivers and Restraints

The global gastrointestinal endoscopy devices market is expected to be fueled by advancements in endoscopy technology. Key drivers of the Gastroscopy Devices Market are increasing cases of esophageal cancer and polyps, growing ageing population, family history of cancer, and changing lifestyle. Increasing government initiatives to diagnose and treat early stage cancers are also expected to fuel gastrointestinal endoscopy devices market. For instance, in 2014, The European Society of Gastrointestinal Endoscopy (ESGE) and United European Gastroenterology (UEG) created a community of endoscopy services across Europe, collaborating with each other to provide high quality, safe, accurate, patient-centered and accessible endoscopic care. The lack of awareness, dearth of experienced professionals, lack of reimbursement policies, and increasing cases associated with bio-dirt is expected to hinder growth of the market.

Gastroscopy Devices Market

Gastroscopy is a type of endoscopy performed for diagnosis of diseases pertaining to esophagus, stomach, and upper part of small intestine. It is also called upper gastrointestinal endoscopy. It is one of the most important discoveries in the field of medical science. Esophagoscope was also a type of endoscopy that was used for diagnosis and treatment procedures of esophagus. Gastroscopy has replaced esophagoscopes completely. The only difference between esophagoscope and gastroscope is the length of gastroscope that is longer than esophagoscopes. Gastroscopy can also be performed to detect cancers. This procedure is recommended to diagnose problems related to the esophagus or stomach. The device has a light and a camera at the end of the probe that is used to see the esophagus, upper intestine and stomach clearly. It is also used to investigate problems related to swallowing, ulcers, and blockage in esophagus. This procedure allows practitioners to study the mucous membrane of the stomach. Gastroscopy are broadly classified into two types namely diagnostic gastroscopy used to diagnose or confirm diagnosis and treatment gastroscopy for therapeutic purposes.  Esophagus cancer is the eighth-most common cancer in the world. As per the report of World Cancer Research Fund International, there were around 456,000 new esophagus cancer cases diagnosed in 2012. Gastroscopy is considered as the most preferred option for screening of esophagus cancer and polyps by most gastroenterologists and thus, the gastrointestinal endoscopy devices market is projected to witness significant traction in the foreseeable future.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/132

High Incidence of Esophageal Cancer Fueling Gastroscopy Devices Market Growth

Esophageal cancer is of two types namely, adenocarcinoma and squamous cell carcinoma. Esophageal cancer can occur due to various reasons such as gene type that includes gene mutations or damage involved in cell divisions. As per results of an independent study, overweight and obesity increases the risk of esophageal cancer by 48% per 5 BMI units. Polyp detection rate of esophagus and stomach depend upon the proportion of mucosal surface diagnosed and correlates to time dedicated for diagnosis. Gastroscopes consist of a flexible tube with a high definition camera at the end of the probe. The quality of camera defines the quality of diagnosis. The long length of device is used to examine the complete length of the esophagus.

Gastroscopy Devices Market: Overview

Technological advancements in gastroscopy technique are expected to drive growth of the market for gastroscopy device, as these significantly improve detection rate as compared to other conventional procedures. Practitioners prefer using flexible gastroscope over non-flexible gastroscopes due to high quality, less breakage problems and high illumination for better imaging provided by the former. Increasing awareness among practitioners of using the advanced gastroscopy over white light traditional gastroscopy is showing a significant growth towards flexible video gastroscopy. Increasing cases of biodirt provides opportunity to gastroscopy manufacturers to introduce products with innovative features to avoid such cases of infections. Hospital end user segment is expected to remain dominant in the market over the foreseeable future.

Key players operating the gastroscopy devices market include Olympus, Karl Storz, Sono Scape, Endomed, Medigus, Fujifilm Holdings Corporation, and Huger.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/gastroscopy-devices-market-132

Key Developments

Major companies in the market are involved in different business strategies such as business expansion, in order to gain competitive edge in the market. For instance, in November 2018, SonoScope Medical Corporation, a China-based endoscopy equipment manufacturer, launched its corporate brand at ISGCON 2018, the 59th Annual Conference of the Indian Society of Gastronomy held at Kerala, India. This expansion will help the company to grow its business in India.

Major companies in the market are involved in different business strategies such as collaboration, agreement, and partnership, in order to enhance their market presence. For instance, in August 2018, Medigus, Ltd., an Israel-based medical device company, entered into an exclusive distribution agreement with Micro-Tech Endoscopy for Medigus’ ‘Medigus Ultrasonic Surgical Endoplaster (MUSE)’ system, which is used for the treatment of heartburn.

Key players in the market are involved in different business strategies such as merger and acquisition, in order to enhance their market presence. For instance, in May 2019, Fujifilm Corporation acquired medwork GmBH, a Germany-based manufacturer of instruments for therapeutic and diagnostic endoscopy.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/132

About Coherent Market Insights:                                                                                                         

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Blood Coagulation Tubes Market Forecast Opportunity Analysis - 2026

 

The global blood coagulation tubes market is projected to grow at a substantial rate over the forecast period. Increase in health awareness among the global population has led to increase in blood diagnostic tests, especially coagulation tests. Increasing prevalence of low platelet count or thrombocytopenia, increased prevalence of liver diseases, as well as growth in number of surgeries are factor that argue well for growth of the market.

Blood coagulation or clotting is the mechanism by which blood changes its form from liquid to a highly viscousgel-like form known as clot. The process is called hemostasis, which prevents blood loss from damaged blood vessels. The process of coagulation consists of activation, bonding, and accumulation of platelets accompanied by deposition and development of fibrin. Thrombosis and hemorrhage are some of the major coagulation disorders.

Coagulation tests primarily measure the body plasma’s ability to clot as well as time taken for the same. Coagulation testing helps doctors assess risk of extreme bleeding or developing thrombosis inside blood vessels. Coagulation tests are conducted in a similar manner as most blood tests. Side effects are minimal in these tests. Coagulation disorders can cause hazardous amounts of blood loss or excessive clotting. If the doctor suspects a coagulation disorder, more coagulation tests may be carried out to confirm the same. These tests are useful for measuring several proteins and their functions. Conditions that can cause clotting disorders include liver disease, thrombophilia (excessive clotting), and hemophilia (inability to clot normally). Moreover, coagulation tests are beneficial for people who take medicines that affects their blood coagulation ability. Coagulation tests are also carried out before certain surgeries depending on the history and condition of the patient.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/139

Blood coagulation tubes primarily contain a solution of tri-sodium citrate. The citrate concentrations are available in two varieties namely0.129 mol/l (3.8%) and0.109 mol/l (3.2%). The mixing ratio is usually one portion citrate to nine portions blood. These tubes also contain adenosine, theophilline, and dipyridamole. One of the most important aspects to be kept in mind is that these tubes must be completely filled, as short draw tubes might not serve the purpose. The side effects of a coagulation test are usually negligible. Patient might experience minor soreness or bruising at the site. The other risks are lightheadedness, pain, and infection(s).

Increased prevalence of thrombosis and liver diseases a major driver for growth of global blood coagulation tubes market

According to American Liver Foundation, in 2013, around 30 million people in the U.S.—a whopping 10% of the population—suffered from some form of liver disease. Liver disease is also considered to be the ‘fifth big killer’ in England and Wales, in 2013, as per the WHO-HFA database. Blood coagulation tubes are widely used for diagnosing thrombosis. According to Center for Disease Control and Prevention (CDC), as many as 900,000 people in the U.S. suffer from thrombosis each year. Fibrinogen activity is tested to evaluate bleeding disorders. They are used to diagnose diseases such as disseminated intravascular coagulation. As per Department of Medicine, University of Alabama at Birmingham, in South Asia, especially in India, the fibrinogen levels are usually high, due to high occurrences of coronary heart diseases and higher levels of wound-induced glycoprotein IIb/IIIa that acts as a receptor for fibrinogen. This in turn will result in increased blood coagulation tests in this region. This creates a highly conducive environment for growth of the blood coagulation tubes industry in the region. A report by Journal of Thrombosis and Hemostatis, emphasizes upon the need for controlled and randomized assessments with clinical result measurement to establish that thromboprophylaxis (prevention of thromboembolic disease or obstruction of blood vessels by blood clot) is essential in joint surgery in Asia.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/blood-coagulation-tubes-market-139

Since blood coagulation tests are usually suggested before and after a surgery, growth in number of surgeries is expected to provide major growth traction to the blood coagulation tubes market. As per independent estimates, around 232 million surgeries are performed worldwide each year. Europe and North America are highest revenue contributors to the global blood clotting tubes market. This is mainly attributed to robust healthcare infrastructure and easy access to advanced healthcare facilities in these regions. However, Asia Pacific is expected to emerge as a high growth region in the global blood coagulation market, due to increase in adoption of blood coagulation tests and high prevalence of heart attack and stroke, along with rising incidence of thrombosis and chronic liver diseases in the region.

Some of the major competitors operating in the blood coagulation tubes industry are Medical Expo, Ajosha BioTeklik Pvt. Ltd., CML Biotech Pvt. Ltd., New MicroMed International Pvt. Ltd., Greiner BioOne, Gosselin, FL Medical, and Advacare Pharma.

Key Developments:

Product launches and continuous innovations by key market players are expected to facilitate growth of the blood coagulation tubes market. For instance, in August 2019, medical device company Q-Sera Pty Ltd. announced that their Q-Sera technology, a blood clotting technology to be used in blood collection tubes, has been granted patent in the U.S. by the United States Patent & Trademark Office.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/139

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Cholestasis Treatment Market Size Share Trends Forecast 2026

 

Technological advancements as well as development of efficient diagnostic tests will ensure early detection of the disease, thereby augmenting growth of the Cholestasis Treatment Market. Cholestasis disease can affect many sides of lipid metabolism. Accumulation of toxic bile constituents in hepatocytes owing to disturbance of the bile from the liver to the gut can harm hepatocytes, which might result into damaged synthetic functionality and lessened production of enzymes concerned in the lipoprotein metabolism. Moreover, lipoprotein discharge is disturbed at some stage in cholestasis, revealed by decline in HDL levels and emergence of the abnormal lipoprotein X in the plasma. Since cholestasis can be linked to a variety of diseases, its treatment is of utmost importance.

The liver plays a pivotal role in control of a variety of aspects of lipid metabolism. Principally, the liver synthesizes bile, ingredients of which are necessary for fat absorption in the intestine. Moreover, biliary discharge of cholesterol and phospholipids into the intestine is of key significance in body lipid homeostasis. Additionally, the liver supplies the plasma lipoproteins; it produces apoproteins that is responsible for regulating many metabolic interconversions amongst lipoprotein classes. It also regulates lipoprotein lipid ingredients such as triglycerides, cholesterol, and phospholipids. Cholestasis is a state in which the bile juice from the liver cannot flow to the duodenum (the first section of the small intestine). There are two basic types of cholestasis – obstructive type of cholestasis, and metabolic types of cholestasis. In obstructive type of cholestasis, there is a blockage in the duct system that carries the bile from the liver, whereas in the metabolic type of cholestasis there is a problem in the formation of bile in the liver. The former can occur due to gallstone or malignancy, while the latter can be genetic or may occur due to side effects of other drugs. Symptoms of cholestasis include itchiness, jaundice, pale stool, and dark urine.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/146

One of the major cholestasis types is obstetric cholestatis. According to the Royal College of Obstetricians and Gynecologists, obstetric cholestasis affects 0.7% of pregnancies in the multiethnic populations in addition to 1.2–1.5% of pregnant women of Indian or Pakistani origin, in England. The prevalence of obstetric cholestasis is shaped by genetic as well as environmental factors. The statistics varies amongst populations worldwide. For instance, 2.4% of all pregnancies are affected in Chile. There is growing prevalence of this disease in the world, which in turn will propel the growth of the overall cholestasis treatment market.

Growing prevalence of obstetric cholestasis to drive growth of the overall cholestasis treatment market

According to a report published in National Center for Biotechnology Information, Intrahepatic cholestasis of pregnancy (ICP) or obstetric cholestasis is the major liver disease during pregnancy. Obstetric cholestasis is characteristically a reversible disease typically occurring in the second to third trimester. It is characterized by pruritus (severe itching of the skin) mainly in the palms and soles, prominent serum aminotransferases coupled with increased serum bile acid levels. As the number of pregnancies is likely to increase in the near future, so is the prevalence of cholestasis. Moreover, cholestasis can be hereditary in nature. There is a significant presence of chronic cholestasis in children owing to the nature of the disease. According to the National Center for Biotechnology Information, hereditary disorders of biliary atresia and intrahepatic cholestasis are the major causes of chronic liver disease amongst children. In children, they also act as the key indicators for liver transplantation. The growing population ensures increased occurrences of the disease amongst children. This in turn will drive growth of the overall cholestasis treatment market during the forecast period.

Some of the major companies operating in the cholestasis treatment market are Eli Lily and Company, Palmetto Health, Asklepion Pharmaceuticals, LLC, and Abbott Laboratories.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/cholestasis-treatment-market-146

Key Developments

Major players in the market are focused on conducting clinical trials to assess their novel therapies for the treatment of cholestasis. For instance, in July 2019, Genkyotex, a biopharmaceutical company, announced positive post-hoc analysis of phase 2 trial that assessed the use of Setanaxib, a NOX-1/4 enzyme inhibitor, for the treatment of cholestatic liver disease.

Research and development related to cholestasis is expected to boost the market growth. For instance, a study presented by the Icahn School of Medicine at Mount Sinai, New York at Digestive Disease Week 2019 in San Diego identified a link between intrahepatic cholestasis of pregnancy and nonalcoholic fatty liver disease.

However, failure of therapies in the treatment of cholestasis is expected to hinder the market growth. For instance, in August 2019, a study by King’s College London published in The Lancet found that treatment with ursodeoxycholic acid does not reduce adverse perinatal outcomes in women suffering from intrahepatic cholestasis of pregnancy.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/146

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Vasculitis Treatment Market Size, Share, Outlook, and Opportunity Analysis, 2018– 2026

 

Vasculitis Treatment Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

A group of disorder caused by the inflammation of blood vessels is known as vasculitis (plural: vasculitides), also called angiitis. Vasculitis includes inflammation of arteries, veins, and/or capillaries. The disease can affect both males and females equally without any age specifications.  Quite a few forms of vasculitis are present, and their scientific characteristics can vary considerably in terms of severity, symptoms, as well as the duration of disease. It depends on the types of blood vessels that are affected by the disease. Vasculitis is a disease which involves the immune system. Here, the immune system stops offering defense aligned with infection and, consequently it fights itself. The precise root of vasculitis is unknown; however, factors triggering the disease include genetic makeup of an individual, blood cancers, immune system diseases (e.g. rheumatoid arthritis), infections (e.g. hepatitis B), and response to certain drugs. Inflammation of blood vessels may lead to several complications. It may block the path of blood flow thereby causing organs to dysfunction.

According to Vasculitis UK, major cause of vasculitis may be hereditary or environmental. Moreover, there is a lack of approved treatment from the regulatory bodies. According to National Center for Biotechnology Information, in 2011, the therapy rituximab (Biogen Idec/Genentech, Rituxan) happened to be the earliest and only FDA-approved possibility for the treatment of vasculitis. This has encouraged the governments and the manufacturers alike, for development of new drugs for vasculitis treatment. Moreover, early detection is one of the key factors for the treatment of the disease. Advent of technology and advanced diagnosis along with support from governments and regulatory bodies around the world will fuel the growth of the global vasculitis treatment market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/150

The American Heart Association says even though it is not established that inflammation of arteries or veins causes cardiovascular disease, however, inflammation is widespread for patients with stroke and heart disease patients and is considered to be an atherogenic (deposition of fat in arteries) response. As the number of cardio vascular diseases in on the rise, patients with opt for diagnosis and treatment of vasculitis. Although it is not proven that inflammation causes cardiovascular disease, inflammation is common for heart disease and stroke patients and is thought to be a sign or atherogenic response; this in turn will propel the growth of the global vasculitis treatment market.

Increase in geriatric population offers a promising future for vasculitis treatment market

According to Vasculitis UK, usually the frequency of occurrence of vasculitis increases from the 50s; however, but infants and young people can be affected as well. According to Administration for Community Living, 46.2 million people in the U.S. were above the age of 65 in 2014. It is estimated that by 2060 there will be around 98 million people falling under this age group. Additionally, latest scientific developments have led to a significant increase in life expectancy around the globe. As the geriatric population increase, so does the propensity of occurrence of vasculitis. As patients have become health aware, and healthcare spend has increased significantly, it can be projected that a part of it will be spent on the diagnosis and treatment of vasculitis; thereby increasing the global vasculitis treatment market.

Manufacturers around the world are competing on the availability of technologically advanced drugs for the treatment of vasculitis. Therefore, there is a significant increase in the research and development spends incurred by the companies. Government support is another positive factor that is in favor of the manufacturers. Some of the companies operating in the global vasculitis treatment market are RNL BIO Co., Ltd., GlaxoSmithKline plc, Novartis AG, Troikaa Pharmaceuticals Ltd., Human Genome Sciences, Inc.¸ Genentech, Inc., F. Hoffmann-La Roche Ltd., Anthera Pharmaceuticals‚ Inc., and Teijin Pharma Limited.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/vasculitis-treatment-market-150

Key Developments

Major players in the market are focused on approval and launch of novel therapeutics intended for the treatment of various types of vasculitis. For instance, in July 2019, Pfizer Inc. announced that its RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan (rituximab), intended for the treatment of adult patients with microscopic polyangiitis, received the U.S. Food and Drug Administration (FDA) approval.

Major institutes and universities are focused on R&D activities related to the treatment of vasculitis. For instance, in August 2019, researchers from Hospital El Bierzo and Burgos University Hospital, Spain, suggested adoption of disease management based on individual patient characteristics and levels of disease severity for the treatment of vasculitis.

Similarly, in August 2019, researchers from Osaka University Graduate School of Medicine, Japan found that intravenous immunoglobulin was associated with rapid improvements in disease activity and the related biomarkers in patients with active ANCA-associated vasculitis.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/150

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Monday, 26 April 2021

Digital Radiography Market To Surpass US$ 7,138.6 Million By 2026 - Coherent Market Insights

 

Global Digital Radiography Market, by Device Type (Direct Radiography (Charged Couple Device (CCD) and Flat Panel Detector), and Computed Radiography), by Application (Chest Imaging, Orthopedic, Cardiovascular Imaging, Dental, and Mammography), by Portability (Fixed and Mobile), by End User (Diagnostic Centers, and Hospitals), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$  5,290.0 million in 2019, and is projected to exhibit a CAGR of 4.2 % over the forecast period (2020 - 2027). Regional governments are focused on improving healthcare infrastructure in emerging economies, which is expected to drive growth of the global digital radiography market. For instance, in 2018, the China Ministry of Health collaborated with the government of China to install computed tomography units in 37 county hospital. The government specifically targeted hospitals located along major highways in order to provide instant diagnosis to victims of emergency cases such as road accidents. Increasing collaborations between regional governments is expected to drive growth of the global digital radiography market. For instance, in 2017, India and Japan government collaborated in the diagnostic sector, and launched a program approved by Ministry of Health of both the countries, to address the diagnostic technological differences between India and Japan.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/151

This program aims to provide healthcare services in remote areas. Moreover, emergence of portable digital radiography systems is driving growth of the global digital radiography market. Fixed radiography systems occupy more space compared to portable systems. Also, screening of patients at the given place is mandated by fixed or mounted digital radiography systems. Portable digital radiography systems on the other hand, allow easy mobility and operability. Additionally, in portable digital radiography systems, images can be sent to the recipient from any location in the hospital, thus saving time and resources. Moreover, portable digital radiography systems can be effective in emergency medical situations.

Browse 43 Market Data Tables and 34 Figures spread through 220 Pages and in-depth TOC on "Global Digital Radiography Market, by Device Type (Direct Radiography(Charged Couple Device (CCD), and Flat Panel Detector), and Computed Radiography), by Application (Chest Imaging, Orthopedic, Cardiovascular Imaging, Dental, and Mammography), by Portability (Fixed and Mobile), by End User (Diagnostic Centers, and Hospitals), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)  - Global Forecast to 2026"

Increasing launches of digital radiography systems are driving growth of the global digital radiography market. For instance, in 2016, Teledyne DALSA launched a portable digital radiography system at the American Society for Nondestructive Testing (ASNT) Annual Conference at California, U.S.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/digital-radiography-market-151

Key Takeaways of the Global Digital Radiography Market:

The global digital radiography market is expected to exhibit a CAGR of xx% over the forecast period (2020-2027) owing to increasing healthcare infrastructure, and healthcare services in remote areas

Among product type, flat panel detector sub segment is expected to account for a major revenue share in 2027, Flat panel detectors (FPD) are used in direct digital radiography (DDR) for the conversion of x-rays to light (indirect conversion) or charge (direct conversion) which is read out using a thin film transistor (TFT) array.

Major players operating in the global digital radiography market include GE Healthcare, North Star Imaging, Fujifilm Holdings, Fresenius Se & Co. KGaA, Philips Healthcare, Shimadzu Corporation, Toshiba Medical System Corporation, Carestream Health, 3DX-Ray, Canon, Inc., and Bosello High Technology.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/151

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Burkholderia Infections Market Size, Trends, Shares, Insights and Forecast – 2018-2026

 

Burkholderia Infections Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Burkholderia infections are caused by Burkholderia cepacia. It is a gram negative bacillus found in aquatic environment. It is a low virulent bacteria and is a frequent colonizer of fluids used in the hospitals such as IV fluid, irrigation solution etc. B. cepacia can cause health problems to some people such as patients suffering from weakened immune system or chronic lung diseases. Burkholderia infection symptom can vary widely in people, ranging from no symptoms to serious respiratory infection. Based on recent genomic subtyping techniques, Burkholderia infection can be transmitted from person to person.  Patients with lung disease such as asthma, CFTR, and COPD are at high risk of suffering from Burkholderia infection. Burkholderia cepacia is resistant to multiple antibiotic such as aminoglycosides, antipseudomonal third-generation cephalosporins and antipseudomonal penicillins.

Increasing prevalence of lung diseases is expected to fuel growth of the Burkholderia infections market. The exact cause for asthma, cystic fibrosis is unknown, though the risk factors can be transferred generation from generation. As per the report of British Lung Foundation, in 2011, an estimated 1.2 million people are living with chronic obstructive pulmonary disease (COPD) and has grown by 27% in the last decade in the U.K. According to the U.S. Cystic Fibrosis Foundation, Europe accounted for the highest number of reported cases of cystic fibrosis in 2012. The growing cases of COPD, asthma and other lung diseases create high risk of burkholderia infection creating an opportunity for manufacturers. Burkholderia infections also cause complications such as soft tissue infections, urinary tract infection and surgical wound infections. It creates an opportunity for the manufacturers to focus on overall treatment. The increasing outbreaks of burkholderia infection has created focus towards the need for proper treatment procedure.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/153

Many organization and government policies have included burkholderia infection as one of the severe infections spread from healthcare facilities. Transmission of B. cepacia from contaminated medicines and medical devices. In 2005, CDC notified several states cluster of pneumonia and other infection caused by B. cepacia associated with contaminated mouthwash. In October, 2016, Nurse Assist Inc, recalled its normal saline flush IV syringes due to Burkholderia Cepacia bloodstream infection. FDA identified this as Class I recall, one of the most serious types of recall which may cause serious injuries or death. In 2004, Burkholderia Cepacia was linked to nosocomial infection among Intensive Care Unit patient and was associated with exposure to sublingual probes. The growing concerns related to contaminated medicines and medical devices are expected to create opportunity for product manufacturers in the burkholderia infections market. The effect of B. cepacia on people varies person to person which leaves the infection with no specific treatment. The unavailability of proper treatment creates hindrance to the overall market. North America is expected to account for maximum share of the global burkholderia infections market, owing to the better diagnostic facilities, increasing awareness and government initiative for early diagnosis and treatment of burkholderia infection. Europe is expected to be the second most lucrative burkholderia infections market.

Burkholderia Infections Market is Highly Fragmented

The market is highly fragmented due to the presence of many emerging players. Major players involved in the burkholderia infections market includes Novabiotics Ltd, iQur Ltd, Aridis Pharmaceuticals LLC, NanoBio Corporation, SUN pharma and others.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/burkholderia-infections-market-153

Key Developments

Continuous research and development activities are expected to facilitate growth of the burkholderia infections market. For instance, in February 2019, the National Institutes of Health (NIH) awarded a US$ 3.34 million grant to researchers at Case Western Reserve University School of Medicine to research and develop a technique for sensitizing Burkholderia multivorans, a common pathogen found in patients with lung diseases, to antibiotics.

Increasing number of investments by regulatory authorities, as well as private organisations to fund R&D activities is driving the market growth. In August 2019, the Biomedical Advanced Research and Development Authority (BARDA), announced a 2-year grant of up to US $20.7 million to VenatoRx Pharmaceuticals, who will then collaborate with BARDA’s Office of the Assistant Secretary for Preparedness and Response (ASPR), and the Department of Defense’s Defense Threat Reduction Agency (DTRA) to test the efficacy of VNRX-5133 compound in treating pathogens, specifically, melioidosis-causing bacterium Burkholderia pseudomallei.

Moreover, in October 2018, Synspira’s candidate therapy, SNSP113, received the orphan drug status from the U.S. Food and Drug Administration (FDA) for treating bacterial infections such as Burkholderia and non-tuberculous Mycobacteria in patients with cystic fibrosis (CF).

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/153

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Sickle Cell Anemia Therapeutics Market Size Share Trends Forecast 2026

 

Increasing occurrence of the disease especially in the Africa region will drive the sickle cell anemia therapeutics market

There is a growing need of early detection and prevention of curable diseases especially among the adults. This is going to be a key opportunity in the Sickle Cell Anemia Therapeutics Market as the percentage of adult population is increasing on a daily basis owing to the rise in life expectancy among the global population. Additionally, the demand for safe and efficacious treatments is gaining prevalence in the market. This factor coupled with unmet medical needs among the patients will fuel the growth of the global sickle cell anemia therapeutics industry.

According to the World Health Organization, around 5% of the population around the globe carries the gene for the sickle cell disease. This percentage is as high as 25% in some of the regions around the world. According to the same report, WHO has estimated that the occurrence of sickle cell disease is highest in the African region. To meet this crisis of high prevalence of the disease, WHO’s governing bodies has taken initiatives to address the same. Moreover, according to PLOS Medicine, the occurrence of sickle cell anemia is likely to rise by around 30% by 2050, especially in the sub-Saharan Africa. This rise in demand will eventually push the global sickle cell anemia therapeutics market into a positive growth trajectory over the course of the forecast period (2016-2024).

Manufacturers around the world are competing on the availability of technologically advanced drugs for the treatment of sickle cell anemia. Key players operating in the global sickle cell anemia therapeutics market are Bristol-Myers Squibb, GlycoMimetics, Pfizer,Anthera Pharmaceuticals Inc., GlycoMimetics, Inc., Eli Lilly, and Mast Therapeutics.Some of the other manufacturers are Daiichi Sankyo, Novartis Pharmaceuticals, Bluebird Bio, HemaQuest Pharmaceuticals Inc., Emmaus Medical, HemaQuest Pharmaceuticals, Baxter, and Merck Sharp & Dohme.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/161

A drastic reduction in the total red blood cells or RBC count or hemoglobin is known as anemia. It can be defined as the inability to carry optimum amount of oxygen by the blood. Sickle-cell diseases (SCD) are types of blood disorders which are usually inherited genetically. One of the common types of SCDs is the sickle-cell anemia or SCA. It essentially gives rise to an irregularity in hemoglobin, the protein that carries oxygen in the blood. Hemoglobin is found typically in the red blood cells of the body. As a result a sickle-like shaped cell is formed under certain conditions. Tribulations in sickle cell disease usually start to take shape at a very early age (within the first year of birth). This might lead to various health problems including pain attacks also known as the sickle-cell crisis, swelling in the limbs, microbial infections, and in certain cases, stroke. Chronic pain may develop with age. Sickle-cell diseases arise when an individual inherits abnormal copies of hemoglobin gene from each parent.

According to Center for Disease Control and Prevention, as of 2016, around 100,000 people in the U.S. are affected by sickle cell diseases or SCDs. Sickle cell diseases are very common among black or African Americans. Around 1 in 13 babies belonging to the race are born with sickle cell diseases. Growing prevalence of the disease will give rise to an increased demand for sickle cell disease prevention and cure, thereby augmenting the growth of the overall sickle cell anemia therapeutics market.

The National Center for Biotechnology Information says that sickle cell anemia is one of the most common hereditary hematological diseases among humans. Annually, around 250,000 children are born with the disease and it is among the most occurring epidemiological genetic diseases worldwide. Governments around the world, especially in Africa are taking initiatives to prevent and cure the disease as a result of which, huge investments on this field are expected in the coming years. This in turn will encourage the manufacturers around the world to manufacture in large quantities to meet the unmet demand thereby propelling the growth of the sickle cell anemia therapeutics market.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/sickle-cell-anemia-therapeutics-market-161

Key Developments

Research and development of novel technologies that may aid in treatment of sickle cell anemia is expected to boost the market growth. For instance, in July 2019, researchers from Florida Atlantic University, in a study published in the journal ACS Sensors, demonstrated a microfluidic impedance assay that can monitor the dynamic cell sickling and unsickling processes. The novel technology is expected to improve the monitoring of sickle cell disease.

Key players in the market are focused on launching platform to screen drugs to treat sickle cell disease. For instance, in August 2019, ReachBio Research Labs started offering a drug screening platform to assess fetal hemoglobin protein induction in drug candidates for the treatment of sickle cell disease.

However, failing clinical trials for the treatment of sickle cell anemia are expected to hinder the market growth. For instance, in August 2019, Pfizer Inc. announced that the Phase III Rivipansel pivotal study, to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease,  failed to achieve its primary or key secondary efficacy endpoints.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/161

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Celiac Disease Drugs Market Size, Share, Outlook, and Opportunity Analysis, 2018– 2026

 

Celiac Disease Drugs Market Outlook: A sea of opportunity beckons

However, stringent regulatory frameworks for drug approval is a major restraint for growth of the global Celiac Disease Drugs Market. Regional segmentation by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. According to the University of Chicago Medicine, Celiac Disease Center, approximately 1% of healthy average Americans are affected by celiac disease. In 2007, 3 million individuals were affected with Celiac Disease and 97% people are undiagnosed and untreated. Around 3 million people were suffering from diabetes type1, out of which 6% (180,000) also had celiac disease; around 610,000 unexplained infertility cases were reported, out of which 6% also suffered from celiac disease. The prevalence of celiac disease in the U.S. in healthy people is 1 in 133 and is estimated at 1 in 56 in people with related symptoms. People with first degree and second degree relatives suffering from celiac disease are 1 in 22 and 1 in 39, respectively. This creates highly lucrative growth opportunities for players in the global celiac disease drugs market, post clinical trials approval. Asia Pacific is likely to show high growth rates in the years post drug approval in the global celiac disease drugs industry, with China and India being the highest revenue contributors.

Celiac disease is an autoimmune disorder that mainly affects the small intestine. It is mainly observed in individual who are hereditarily inclined towards gluten. Celiac disease symptoms include gastrointestinal malfunction such as diarrhea, abdominal distention, loss of appetite, and among kids failure to grow normally and also sometimes loss of lymphocytes.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/168

Coeliac disease is triggered by a bodily reaction to gluten, generally found in wheat and in other grains such as barley and rye. As the mechanism of action is still shrouded in an air of uncertainty, many pharmaceutical companies are conducting clinical trials to develop specific products to treat celiac disease. The success of the celiac drug innovation would be a big milestone for any pharmaceutical company in celiac disease drugs market.

100% gluten-free diet is the only existing treatment for celiac disease

According to National Foundation for Celiac Awareness (NFCA), celiac disease affects both men and women of all age groups and races. It is estimated that around 83% of all local Americans who have celiac disease are untreated or misdiagnosed with other bowel disorders. People with untreated celiac disease incur additional average medical costs of US$ 3,964 as compared to healthy individuals. Of all the people diagnosed with celiac disease, 5-22% have an immediate family member who was diagnosed with celiac disease. There are no specific drugs to treat celiac diseases. The total number of individuals diagnosed in the U.K. with celiac disease has increased fourfold between 1990 and 2011, from 5.2 per 100,000 to 19.1 per 100,000. This inadvertently creates a highly conducive environment for growth of the celiac disease drugs market, once such a drug is commercialized in the market.

Celiac Disease Drugs Market Scenario: Bowel biopsy the only available method to confirm celiac disease

The celiac disease drugs are still undergoing clinical trials. It is challenging to identify celiac disease in the primary stages, as the symptoms are deceptively similar to those of other bowel disorders. Various subtle and selective blood tests such as anti-tissue transglutaminase antibodies are used to screen the disease. If the test results are positive, then the individual is asked to undergo a small bowel biopsy to confirm the disease, as there is no specific or defined treatment. Extensive R&D activities currently underway are expected to pave way for more effective and advanced diagnostic options and innovative drugs, in turn positioning the global celiac disease drugs market on high growth trajectory.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/celiac-disease-drugs-market-168

Major players in the Global Market

Key players operating the market include Alvine Pharmaceuticals, Inc., Alba Therapeutics Corporation, ImmusanT, and the Institute for Protein Design. All the above mentioned companies have their celiac disease drugs in clinical trial phase I and II.

Key Developments in the Global Market

Key players in the market are focused on approval and launch of novel drugs intended for the treatment of celiac disease. For instance, in August 2019, ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation, announced that the U.S. Food and Drug Administration (FDA) granted an Investigational New Drug (IND) application for AG017, an orally-delivered drug for the treatment of celiac disease.

Moreover, in August 2019, Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company based in the U.S., announced first patient enrollment in its Phase III clinical trial, CeD LA 3001 for Larazotide acetate, a drug candidate for the treatment of celiac disease.

Major institutes and universities are focused on R&D activities related to celiac disease. For instance, in August 2019, researchers from the Massachusetts General Hospital and The Walter and Eliza Hall Institute, Australia, found that gluten-specific CD4+ T cells are rapidly reactivated by antigen -exposure likely causing celiac disease-associated gastrointestinal symptoms. The development is expected to offer diagnostic blood test for celiac disease.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/168

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


Phosphodiesterase Enzyme (PDE) Inhibitors Market Opportunity Analysis - 2026

 

Phosphodiesterase Enzyme (PDE) Inhibitors Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Phosphodiesterase are a diverse family of enzymes (11 isoenzymes) that play a key role in regulating intracellular levels of secondary messengers - cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate. These enzymes identified to be pharmacologically active in the 1950s, hydrolyses cyclic nucleotides to treat various diseases such as cardiovascular, respiratory and erectile dysfunction. Distinct distribution of all the types of isoenzymes has provided possibilities for selective target therapies.

The global phosphodiesterase enzyme inhibitors market can be better analyzed by classifying it into two classes as selective phosphodiesterase enzyme inhibitors and non-selective phosphodiesterase enzyme inhibitors. Theophylline and papaverineare the two most commonly used non-selective phosphodiesterase enzyme inhibitors for treating a range of diseases (bronchodilation, cardiac disorder, etc.). Advent of selective phosphodiesterase enzyme inhibitors has made a great impact in the medical treatment sector. Increasing understanding of the individual PDE isoforms has and will result in the emergence of better therapeutic drugs. Viagra (Sildenafil) is the best example to substantiate the success and impact of PDE inhibitors.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/172

The global phosphodiesterase enzyme inhibitors market is majorly driven by PDE-5 inhibitors realizing the success of blockbuster drugs in these segment.

Increasing product developments to further improvise the phosphodiesterase enzyme inhibitors market outlook

The global phosphodiesterase enzyme inhibitors market has recently gained traction on account of the blockbuster PDE 5 inhibitor brands, Viagra and Cialis. This has also encouraged pharmaceutical companies to research on other PDE inhibitor class. In addition, research on extended use of approved PDE inhibitors is anticipated to benefit the drug in long term and contribute to the increasing revenues of PDE inhibitors market.

Researchers from the John Hopkin University reviewed the trials of PDE-5 inhibitors in pediatric patients with pulmonary hypertension. The researchers concluded that PDE-5 inhibitors can be safely prescribed to infants, neonates and children with primary and secondary pulmonary hypertension (2017).

Besides, PDE-5 inhibitor sildenafil accidently developed for treating angina, was also found to be effective in erectile dysfunction and now is observed to benefit heart attack patients. Researchers at Karolinska Institutet, Sweden reported in March 2017 that PDE-5 inhibitors prescribed for erectile dysfunction can lower the risk of death of hospitalization for heart failure in men who have had one heart attack in their lifetime.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/phosphodiesterase-enzyme-inhibitors-market-172

Pfizer, Inc. received FDA approval for its PDE-4 inhibitor Crisaborole (Eucris) in December 2016 for the treatment of mild to moderate atopic dermatitis. Eucrisa the first non-steroidal topical monotherapy for skin disorder.

Many such product developments would be augmenting the global PDE inhibitors market growth in near future.

New products are primarily targeted in develop economies like North America, Europe and Japan. However, product approval in emerging nations such as India, China, Brazil, Russia, Argentina, and Indonesia would potentially favorable for the market players. Increasing healthcare expenditure and large target population base would support the growth of PDE inhibitors market in these nations. However, market players need to be cautious about uncertain regulatory conditions favoring the economic status and healthcare need of the large patient population.

Some of the key players operating in the global phosphodiesterase enzyme inhibitors market include Pfizer, Inc., AstraZeneca plc, Bayer AG, Eli Lilly & Company, Celgene Corporation, Mist Pharmaceuticals.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/172

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737